BIO-RAD LABORATORIES -CL B (BIO.B) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock
BIO.B Key Statistics, Chart & Performance
The current stock price of BIO.B is 310.7 USD. In the past month the price decreased by -8.89%. In the past year, price decreased by -48.29%.
BIO.B Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.38 | 221.98B | ||
| DHR | DANAHER CORP | 29.41 | 160.19B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 186.73 | 56.74B | ||
| A | AGILENT TECHNOLOGIES INC | 27.51 | 43.52B | ||
| IQV | IQVIA HOLDINGS INC | 19.78 | 39.17B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.29 | 30.17B | ||
| WAT | WATERS CORP | 31.77 | 24.02B | ||
| ILMN | ILLUMINA INC | 30.15 | 20.09B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.21 | 19.95B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.43 | 16.69B | ||
| TEM | TEMPUS AI INC | N/A | 13.86B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B |
Related stock screener links
About BIO.B
Company Profile
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Company Info
BIO-RAD LABORATORIES -CL B
1000 Alfred Nobel Dr
Hercules CALIFORNIA US
CEO: Norman Schwartz
Employees: 7700
Phone: 15107247000
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What does BIO-RAD LABORATORIES -CL B do?
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
What is the stock price of BIO-RAD LABORATORIES -CL B today?
The current stock price of BIO.B is 310.7 USD. The price decreased by -1.18% in the last trading session.
Does BIO-RAD LABORATORIES -CL B pay dividends?
BIO.B does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIO.B stock?
BIO.B has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about BIO-RAD LABORATORIES -CL B (BIO.B) stock?
10 analysts have analysed BIO.B and the average price target is 363.55 USD. This implies a price increase of 17.01% is expected in the next year compared to the current price of 310.7.
What is the Price/Earnings (PE) ratio of BIO-RAD LABORATORIES -CL B (BIO.B)?
The PE ratio for BIO-RAD LABORATORIES -CL B (BIO.B) is 30.14. This is based on the reported non-GAAP earnings per share of 10.31 and the current share price of 310.7 USD.
Can you provide the ownership details for BIO.B stock?
You can find the ownership structure of BIO-RAD LABORATORIES -CL B (BIO.B) on the Ownership tab.
BIO.B Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BIO.B. When comparing the yearly performance of all stocks, BIO.B is a bad performer in the overall market: 83.24% of all stocks are doing better.
BIO.B Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability.
BIO.B Financial Highlights
Over the last trailing twelve months BIO.B reported a non-GAAP Earnings per Share(EPS) of 10.31. The EPS decreased by -1.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| Debt/Equity | 0.18 |
BIO.B Forecast & Estimates
10 analysts have analysed BIO.B and the average price target is 363.55 USD. This implies a price increase of 17.01% is expected in the next year compared to the current price of 310.7.
For the next year, analysts expect an EPS growth of -1.6% and a revenue growth 0.42% for BIO.B